Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,694 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Nashville, Tennessee Clear all
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Single Dose Pharmacokinetic (PK) Study

NCT03109756
View directory record Official record
Conditions
Angelman Syndrome, Fragile X Syndrome
Interventions
OV101
Drug
Lead sponsor
Healx AI
Industry
Eligibility
13 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Phase 2 Interventional

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Platinum-based chemotherapy, REGN7075
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
15
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

NCT00640042
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate extended release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
378
States / cities
Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266
View directory record Official record
Conditions
Myelodysplastic Syndrome, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

NCT03088813
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Irinotecan liposome injection, Topotecan
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 1 Interventional Results available

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

NCT03248479
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Magrolimab, Azacitidine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
26
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

NCT01574703
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
65
States / cities
Mobile, Alabama • Encino, California • Escondido, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jul 23, 2026, 6:24 AM EDT
Not yet recruiting Not applicable Interventional

Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)

NCT07527273
View directory record Official record
Conditions
Aging, Depression, Cognitive Symptoms
Interventions
Depression Cognitive Training, Non-Specific Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation)
Behavioral · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional

Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids

NCT01311869
View directory record Official record
Conditions
Leiomyoma
Interventions
EGCG ( Green Tea extract), Brown rice pills
Dietary Supplement
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

NCT05071183
View directory record Official record
Conditions
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
TPX-0005, Trametinib
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
California City, California • Denver, Colorado • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Results available

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

NCT00500903
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

NCT01583283
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215, lenalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

PATHFINDER 2: A Multi-Cancer Early Detection Study

NCT05155605
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
35,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
55
States / cities
Auburn, California • Davis, California • Elk Grove, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Chronic Pain Skills Study - Vanderbilt University Medical Center

NCT03384953
View directory record Official record
Conditions
Chronic Pain
Interventions
Clinical Hypnosis - Group Treatment, Clinical Hypnosis - Individual Treatment
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Laryngeal Mask Airways in Sinonasal Surgery

NCT02311153
View directory record Official record
Conditions
Conditions Requiring Sinonasal Surgery
Interventions
Mallinckrodt Endotracheal Tube (ETT), Laryseal Laryngeal mask airway (LMA)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

NCT02820961
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
entinostat, exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Phase 1 Interventional

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

NCT06521554
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
NVL-330
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Irvine, California • Sacramento, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

NCT02722954
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
Demcizumab, Pembrolizumab
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Denver, Colorado • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting No phase listed Observational

Early Detection of Lung Cancer

NCT03181256
View directory record Official record
Conditions
Lung Cancer
Interventions
Biospecimen collection, Pulmonary Function Test, Computed Tomography (CT), Laboratory Biomarker
Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
55 Years to 80 Years
Enrollment
45 participants
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

NCT00057720
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
234
States / cities
Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Jul 23, 2026, 6:24 AM EDT